Cencora plans to invest over $1 billion in expanding its U.S. network by 2030, with a new distribution center in Ohio and expanded sites in California and Alabama. The move aligns with the Trump administration’s push for domestic pharmaceutical manufacturing to strengthen the U.S. supply chain for critical medicines.

The new Ohio distribution center, set to open by spring 2027, will feature advanced automation and increased storage capacity. Cencora also plans to open a larger distribution center in California by fall 2026. The company expects adjusted profit per share for 2026 to be between $17.45 and $17.75, exceeding analyst expectations.

Cencora and peers like Cardinal Health are benefiting from surging U.S. demand for specialty medicines, with sales at the company’s U.S. Healthcare Solutions unit increasing by 5.7% to $75.79 billion in the last quarter. Strong prescription volumes of weight loss and diabetes drugs, along with specialty medicines, are driving growth for the company.

In the fourth quarter, Cencora reported a profit of $3.84 per share, beating analyst estimates of $3.79 per share. Total sales for the quarter were $83.73 billion, surpassing estimates of $83.46 billion. The company’s strong performance reflects the growing demand for high-margin specialty medicines in the U.S. market.

Read more at Yahoo Finance: Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast